• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapy and medication isn't effective. A customized treatment may be the solution.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into personalised micro-interventions that improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet only half of those with the condition receive treatment. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to benefit from certain treatments.

The treatment of Depression (hikvisiondb.webcam) can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from certain treatments. They make use of sensors for mobile phones, a voice assistant with artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to discover biological and behavior factors that predict response.

So far, the majority of research into predictors of depression treatment effectiveness has centered on clinical and sociodemographic characteristics. These include demographic variables like age, sex and education, clinical characteristics including the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

Few studies have used longitudinal data to predict mood of individuals. They have not taken into account the fact that mood varies significantly between individuals. Therefore, it is critical to create methods that allow the identification of individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can systematically identify different patterns of behavior and emotions that differ between individuals.

The team also devised an algorithm for machine learning to identify dynamic predictors of the mood of each person's depression. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. However the correlation was not strong (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely across individuals.

Predictors of symptoms

depression treatment ect is among the world's leading causes of disability1 but is often not properly diagnosed and treated. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many from seeking treatment.

To facilitate personalized treatment to improve treatment, identifying the factors that predict the severity of symptoms is crucial. Current prediction methods rely heavily on clinical interviews, which aren't reliable and only detect a few features associated with depression.

Machine learning can enhance the accuracy of diagnosis and home treatment for depression for depression by combining continuous digital behavioral phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements and capture a variety of distinctive behaviors and activity patterns that are difficult to record using interviews.

The study involved University of California Los Angeles (UCLA) students experiencing mild to severe depressive symptoms participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were sent online for support or to clinical treatment based on the degree of their depression. Those with a CAT-DI score of 35 or 65 were assigned to online support with an online peer coach, whereas those with a score of 75 patients were referred to psychotherapy in person.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. The questions included age, sex and education as well as financial status, marital status and whether they were divorced or not, their current suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression-related symptoms on a scale from 0-100. CAT-DI assessments were conducted each other week for participants who received online support and once a week for those receiving in-person care.

Predictors of Treatment Response

Research is focusing on personalization of treatment for depression. Many studies are aimed at finding predictors, which can help clinicians identify the most effective medications to treat each patient. Pharmacogenetics, for instance, identifies genetic variations that determine the way that our bodies process drugs. This enables doctors to choose the medications that are most likely to be most effective for each patient, reducing the time and effort involved in trials and errors, while avoiding side effects that might otherwise slow progress.

Another approach that is promising is to build models of prediction using a variety of data sources, including data from clinical studies and neural imaging data. These models can be used to determine which variables are most likely to predict a specific outcome, like whether a medication will improve symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness of their treatment.

A new era of research uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables to improve predictive accuracy. These models have proven to be useful in forecasting treatment outcomes, such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and could be the norm in future treatment.

Research into depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that an individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.

One method to achieve this is by using internet-based programs which can offer an individualized and personalized experience for patients. One study found that an internet-based program improved symptoms and led to a better quality of life for MDD patients. Furthermore, a randomized controlled study of a customized approach to depression treatment showed sustained improvement and reduced adverse effects in a significant percentage of participants.

Predictors of Side Effects

In the ect treatment for depression and anxiety of depression, a major challenge is predicting and determining the antidepressant that will cause no or minimal side negative effects. Many patients take a trial-and-error approach, using various medications prescribed until they find one that is safe and effective. Pharmacogenetics offers a fresh and exciting way to select antidepressant medicines that are more effective and precise.

There are many variables that can be used to determine the antidepressant that should be prescribed, such as gene variations, phenotypes of patients like gender or ethnicity, and the presence of comorbidities. To identify the most reliable and accurate predictors for a particular treatment, randomized controlled trials with larger sample sizes will be required. This is because the identifying of interaction effects or moderators can be a lot more difficult in trials that only focus on a single instance of treatment per participant, rather than multiple episodes of treatment over a period of time.

Furthermore, predicting a patient's response will likely require information on the comorbidities, symptoms profiles and the patient's own perception of effectiveness and tolerability. Presently, only a handful of easily measurable sociodemographic and clinical variables seem to be correlated with the response to MDD, such as gender, age race/ethnicity, BMI, the presence of alexithymia and the severity of depressive symptoms.

Many challenges remain in the application of pharmacogenetics in the treatment of depression. First, it is important to be able to comprehend and understand the definition of the genetic factors that cause depression, as well as an accurate definition of an accurate predictor of treatment response. Ethics like privacy, and the ethical use of genetic information must also be considered. In the long run pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and improve the treatment outcomes for patients with depression. As with any psychiatric approach it is crucial to give careful consideration and implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that work and encourage them to speak openly with their doctors.